Journal: Cancers
Article Title: Mesothelin-Associated Anti-Senescence Through P53 in Pancreatic Ductal Adenocarcinoma
doi: 10.3390/cancers17122058
Figure Lengend Snippet: Figure 6. The proposed model of the mesothelin (MSLN)-mediated anti-senescence mechanism (MAAS) in pancreatic ductal adenocarcinoma (PDAC). (A) In PDAC cells with high MSLN expres- sion, oncogenic signaling pathways such as PI3K/AKT/mTOR, ERK/MAPK, and FAK/SRC/NF-κB are activated. These promote cell proliferation, survival, and migration while suppressing cellular senescence and apoptosis. (B) In MSLN-deficient PDAC cells, the loss of MSLN leads to the accu- mulation of DNA damage and the activation of the DNA damage response (DDR), as evidenced by increased γH2AX expression. This triggers the upregulation of p53, p21waf1, and p16ink4a, re- sulting in cell cycle arrest and the acquisition of senescence phenotypes. Senescent PDAC cells also produce elevated levels of IL-8, a key component of the senescence-associated secretory phenotype (SASP). Collectively, this model illustrates how MSLN suppresses senescence and facilitates tumor progression, representing a novel mechanism termed mesothelin-associated anti-senescence (MAAS).
Article Snippet: Human PDAC cell lines AsPC1, CFPAC1, MIA Paca2, and Panc1 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in Yao Lab. Human PDAC cell line Panc28 was obtained from MD Anderson Dr. Craig Logsdon’s lab. Murine PDAC Panc02 cell line was obtained as a gift from Dr. Sabry EL-Naggar, the Medical University of South Carolina [20].
Techniques: Protein-Protein interactions, Migration, Activation Assay, Expressing